Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Strategic Perspectives: Prostate Cancer - Issues in Second-line, Brachytherapy and Hormone-Refractory Prostate Cancer Treatments

Published by: Datamonitor

Published: Oct. 21, 2002 - 198 Pages


Table of Contents


Overview

Introduction

Although highly treatable at initial stages, there remains lack of consensus in second-line and hormone-refractory prostate cancer therapies and as a result, treatment practices vary considerably from country to country. This is a detailed analyses of the current treatment standards for second-line and HRPC treatments in seven major markets and profiles drugs currently in development for prostate cancer. Brachytherapy, and the major players in the market are also analyzed.




Scope

Results of extensive physician research across the seven major markets: US, Japan, Germany, France Italy, Spain and UK

Main treatment regimens in second-line and HRPC treatments in the 7 major markets

Physicians’ opinion on brachytherapy

Profiles and potential of drugs in development for prostate cancer

Unmet needs in the treatment of prostate cancer




Report Highlights

Although some physicians have expressed doubts about the clinical effectiveness of brachytherapy, Datamonitor believes that its use will become more common as techniques and technology improve. The treatment of HRPC remains fragmented. However, Datamonitor believes that Taxotere alone or in combination with existing agents, will become the gold-standard therapy. Despite the poor trial results for NSCLC, opinion leaders still believe that Iressa is key to the long-term future of HRPC treatment.




Reasons to Purchase

Identify the key regimens used for second-line and HRPC treatment in the seven major markets

Assess expert opinion views on the current treatment standards for second-line and HRPC to determine the future trends in the market

Evaluate key drugs in late-stage development for prostate cancer to enhance your commercial positioning of your product

Predict the future potential of brachytherapy in the prostate cancer market by ascertaining physicians’ view on the treatment




DRIVERS AND TRENDS

The treatment of prostate cancer after first-line failure is dogged with controversy.

What are the main treatment regimens used in second-line for prostate cancer?

LHRH agonists and anti-androgens remain the mainstay of second-line prostate cancer treatment




BRACHYTHERAPY

Despite its growing popularity, brachytherapy has failed to gain wide acceptance among physicians in the major markets

Assessing physicians’ opinion on brachytherapy in the seven major markets

Physicians’ perception of leading brachytherapy manufacturers




HORMONE-REFRACTORY PROSTATE CANCER

Treatment options for the treatment of hormone-refractory prostate cancer remain fragmented in the seven major markets

Determining the common regimens used for HRPC

Evaluating physicians’ view on the chemotherapy for HRPC




DRUGS IN DEVELOPMENT

This section examines current drugs that being developed for the treatment of prostate cancer, including HRPC

SWOT analyses of current drugs in development for prostate cancer

What are the pipeline drugs with the most potential?




DATASETS

Table 1: Common second-line regimens used for prostate cancer in the seven major markets, 2002

Table 2: Currently used regimens for HRPC in the seven major markets, 2002

Table 3: Pipeline drugs rated by physicians to have the highest potential in the treatment of prostate cancer, 2002

Table 4: Physicians’ perception of brachytherapy for the treatment of prostate cancer

Table 5: Estimated number of prostate cancer patients progressing to second-line treatment, 2002

Table 6: Prevalent population of HRPC in the seven major markets in 2002

Table 7: Proportion of prostate cancer patients progressing to second-line treatment in the seven major markets, 2002

Table 8: Estimated number of prostate cancer patients progressing to second-line treatment, 2002

Table 9: Five-year survival rates for prostate cancer at each stage, 2002

Table 10: Proportion of second-line patients receiving further hormonal treatment after TAB in first-line in the seven major markets, 2002

Table 11: Circumstances where further hormonal therapy is used in second-line after first-line failure, 2002

Table 12: Non-clinical factors that affect second-line prescription for prostate cancer in the seven major markets, 2002

Table 13: US approval and patent expiry dates for Lupron, Zoladex and Casodex

Table 14: Common drugs used in second-line therapy for prostate cancer

Table 15: Common second-line regimens used for prostate cancer in the seven major markets, 2002

Table 16: Price per mg of commonly used second-line drugs for prostate cancer, 2002

Table 17: Cost of common treatment regimens for second-line therapy of prostate cancer ($) in 2002

Table 18: Percentage of patients achieving PSA response with conventional external beam radiation and 3DCRT

Table 19: Proportion of radiotherapy used for prostate cancer, 2001

Table 20: Comparison between prostatectomy, external beam radiation and brachytherapy

Table 21: Physicians’ perception of brachytherapy

Table 22: Physicians’ perception of leading companies in brachytherapy in the seven major markets, 2002

Table 23: Physicians’ perception of brachytherapy use in five years’ time

Table 24: Prevalent population of HRPC in the seven major markets in 2002

Table 25: Proportion of prostate cancer patients progressing to HRPC in the seven major markets in 2002

Table 26: Number of lines of treatment failed before progressing to HRPC

Table 27: Number of months before progressing to HRPC

Table 28: Physicians’ opinion on chemotherapy for HRPC treatment

Table 29: Clinical trial results involving estramustine for HRC

Table 30: Clinical trials involving docetaxel and estramustine

Table 31: Factors influencing chemotherapy prescribing for HRPC

Table 32: Currently used regimens for HRPC in the seven major markets, 2002

Table 33: Average survival duration for HRPC patients, 2002

Table 34: Price per mg of commonly used drugs for HRPC, 2002

Table 35: Average cost of HRPC regimens for three months or cycles in 2002 ($)

Table 36: Cost of treatment per month of survival ($), 2002

Table 37: Physicians’ awareness of pipeline drugs for prostate cancer

Table 38: Percentage of physicians interviewed rating pipeline drugs with the highest potential

Table 39: Phase I study of oral intermittent Iressa

Table 40: Physicians’ perception of leading companies in prostate cancer

Table 41: Physicians’ perception of current and investigational drugs likely to make the biggest impact in prostate cancer management in 5 years’ time

Table 42: Unmet needs in prostate cancer according to physicians interviewed, 2002

Table 43: Percentage of patients with PSA levels increasing above 4ng/mL over five years

Table 44: Commonly used preventative drugs for prostate cancer in the seven major markets, 2002

Table 45: Key sources of diagnosis guidelines used in key markets

Table 46: Key sources of treatment guidelines used in key markets

Table 47: Staging split in the seven markets

Table 48: Cost comparisons of drugs for second-line and HRPC treatment in the seven major countries

Abstract

Introduction: Although highly treatable at initial stages, there remains lack of consensus in second-line and hormone-refractory prostate cancer therapies. As a result, treatment practices vary considerably from country to country. Furthermore, brachytherapy, despite its growing popularity in recent years, has not been widely adopted. This study presents the results of extensive physician research to identify existing treatment regimens, profiles new drugs in development, and highlights areas of unmet need. Scope: * Results of extensive physician research across the seven major markets: US, Japan, Germany, France Italy, Spain and UK * Main treatment regimens in second-line and HRPC treatments in the 7 major markets * Physicians' opinion on brachytherapy * Profiles and potential of drugs in development for prostate cancer * Unmet needs in the treatment of prostate cancer. Report Highlights: Although some physicians have expressed doubts about the clinical effectiveness of brachytherapy, Datamonitor believes that its use will become more common as techniques and technology improve. The treatment of HRPC remains fragmented. However, Datamonitor believes that Taxotere alone or in combination with existing agents, will become the gold-standard therapy. Despite the poor trial results for NSCLC, opinion leaders still believe that Iressa is key to the long-term future of HRPC treatment. Reasons to Purchase: * Identify the key regimens used for second-line and HRPC treatment in the seven major markets * Assess expert opinion views on the current treatment standards for second-line and HRPC to determine the future trends in the market * Evaluate key drugs in late-stage development for prostate cancer to enhance your commercial positioning of your product * Predict the future potential of brachytherapy in the prostate cancer market by ascertaining physicians' view on the treatment

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008